Journals / MN Oftalmoloji / 2013 / Cilt: 20 - Sayı: 1

Effect of topical 2% cyclosporin and oral acyclovir on herpetic non-necrotizing stromal keratitis

Nekrozsuz stromal herpetik keratit tedavisinde oral asiklovir ve topikal %2 siklosporinin etkinliği

Pages
4–8
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cyclosporine may be especially more effective in the visual acuity, stromal haze, and neovascularization

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study is to compare the efficacy of the treatment of non-necrotizing herpetic stromal keratitis with topical 2% cyclosporine versus 1% prednizolon acetate.
📊
Key Findings & Data:Thirty one eyes of 31 patients with non-necrotizan herpetic keratitis were included in the study and randomly devided into two groups as patients treated with %2 cyclosporine (n=16) and patients treated with prednisolone acetate (n=15).
💡
Conclusion & Impact:Cyclosporine may be especially more effective in the visual acuity, stromal haze, and neovascularization
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study is to compare the efficacy of the treatment of non-necrotizing herpetic stromal keratitis with topical 2% cyclosporine versus 1% prednizolon acetate. Material and Method: A randomized, controlled prospective study was designed. Thirty one eyes of 31 patients with non-necrotizan herpetic keratitis were included in the study and randomly devided into two groups as patients treated with %2 cyclosporine (n=16) and patients treated with prednisolone acetate (n=15). Oral acyclovir was administered 800 mg 3 times per day for 8 weeks and then tapered by 800 mg per day one year in both groups. All patients follow-up for at lest 1 year. Stromal haze, visual acuity, healing time of cornea and corneal neovascularization were compared in patients. Results: There was no significiant difference in the mean age of patients, visual acuity, degree of corneal stromal haze and corneal neovascularization before treatment in both groups (p>0.05). Stromal herpetic keratitis resolved in patients treated with 2% cyclosporin in mean 4.19+98 weeks and with prednisolone acetate in mean 4.87+91 weeks. There was no significiant differences in the resolving and mean healing time of inflamation (p>0.05) between the two groups. Stromal haze and corneal neovascularization were significiantly less in patients treated with 2% cyclosporin (p<0.01) in comparison with patients treated with 1% prednisolone acetate. Visual acuity was significiantly better in patients treated with 2% cy-taclosporine in comparison with patients treated with 1% prednisolone acetate (p<0.05). Conclusion: Our study shows that stromal herpetic keratitis can be treated effectively with 2% topical cyclosporine. Cyclosporine may be especially more effective in the visual acuity, stromal haze, and neovascularization

Özet

Amaç: Çalışmamızın amacı non-nekrotizan (nekrozsuz) stromal herpetik keratit tedavisinde topikal %2 siklosporin ve %1 prednizolon asetatın etkinliğini karşılaştırılmaktı. Gereç ve Yöntem: Çalışma randomize (rastgele), kontrollü ve prospektif (geleceğe dönük) olarak planlandı. Non-nekrotizan (nekrozsuz) herpetik keratitli otuzbir hasta (31 göz) çalışmaya dahil edildi, rastgele olarak iki gruba ayrıldı. Siklosporin grubundaki hastalar (n=16) %2 siklosporin, prednizolon grubundaki hastalar (n=15) %1 prednizolon asetat ile tedavi edildi. Her iki gruba da oral asiklovir önce 2400 mg/gün 8 hafta, takiben 1 yıl boyunca 800 mg/gün idame tedavisi olarak verildi.Tüm hastalar en az 1 yıl takip edildi. Hastalar görme keskinliği, iyileşme süresi, stromada bulanıklık ve yeni damarlanma açısından karşılaştırıldı. Bulgular: Tedavi öncesinde hastaların yaşları, görme keskinlikleri, stroma bulanıklıkları ve neovaskülarizasyon dereceleri arasında istatistiksel olarak anlamlı farklılık saptanmadı (p>0,05). Siklosporin kullanan tüm hastalarda ortalama 4,19±0,98 haftada stroma keratiti iyileşirken, prednizolon kullanan hastalarda ortalama 4,87±0,91 haftada iyileşti. Gruplar arasında enflamasyonun iyileşme süresi arasında istatistiksel olarak anlamlı fark yoktu (p>0,05). Siklosporin tedavisi stromada bulanıklık (p>0,05) ve kornea yeni damar oluşumundaki gerileme (p<0.05) üzerine daha etkin bulundu. Görme keskinliğinde artış prednizolon grubuna göre siklosporin grubunda istatistiksel olarak daha anlamlı idi(p<0,05). Sonuç: Bizim çalışmamız stromada herpetik keratitin %2 topikal siklosporin ile etkili bir şekilde tedavi edilebileceğini gösterdi. Siklosporin özellikle görme keskinliği, stromal bulanıklık ve yeni damar oluşumu üzerinde daha etkin bulundu.

🔖

Cite This Article

VURAL, E. T., OKUTUCU, M. (2013). Effect of topical 2% cyclosporin and oral acyclovir on herpetic non-necrotizing stromal keratitis. MN Oftalmoloji, Cilt: 20 - Sayı: 1, 4–8. https://ajindex.com/articles/295610

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Çakmakçı Ş, Akova A, Aydın P. Oküler herpeste ön segment bulguları ve tedavisi. T Klin J Oftalmoloji 2000;9:69-76 2. Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis. Cornea1999;18:127-43 3. Holland EJ, Schwartz GS Classification of herpes simplex virus keratitis. Cornea1999;18:144-54. 4. Kaye S, Choudhary A. Herpes simplex keratitis.Prog Retin Eye Res 2006;25:355-80. 5. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998;339:300-6 6. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol 1999;237:435-8 7. Rao SN.Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol 2006;141:771-2. 8. Yoon KC, Heo H, Kang IS, Lee MC, Kim KK, Park SH, et al. Effectof topical cyclosporin A on herpetic stromal keratitis in a mouse model. Cornea 2008;27:454-60. 9. Liesegang TJ.Herpes simplex virus epidemiology and ocular importance. Cornea 2001;20:1-13 10. Wilhelmus KR, Gee L, Hauck WW; et al. Herpetic Eye Disease Study: acontrolled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994;101: 1883-96 11. Guess S, Stone DU, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf 2007;5:240-50. 12. Doymaz MZ, Rouse BT.Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes. Invest Ophthalmol Vis Sci 1992;33:2165-73. 13. Tang Q, Chen W, Hendricks RL. Proinflammatory functions of IL-2 in herpes simplex virus corneal infection. J Immunol 1997;158:1275-83 14. Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence- based review. Surv Ophthalmol 2009;54:226-34. 15. Donnenfeld E, Pflugfelder SC.Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009;54:321-38 16. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate- to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-74. 17. Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthal mo - logy 2004;111